Curriculum vitae for mark cushman - Purdue College of Pharmacy ...

14
Mark Cushman
198. A. B. Edsall, A. K. Mohanakrishnan, D. Yang, P. E. Fanwick, E. Hamel, A. D. Hanson,
G. Agoston, and M. Cushman, "Effect of Altering the Electronics of 2-Methoxyestradiol
on Cell Proliferation, on Cytotoxicity in Human Cancer Cell Cultures, and on Tubulin
Polymerization," J. Med. Chem. 47, 5126-5139 (2004).
199. M. Nagarajan, A. Morrell, B. C. Fort, M. R. Meckley, S. Antony, G. Kohlhagen, Y.
Pommier, and M. Cushman, "Synthesis and Anticancer Activity of Simplified
Indenoisoquinoline Topoisomerase I Inhibitors Lacking Substitutions on the Aromatic
Rings, J. Med. Chem. 47, 5651-5661 (2004).
200. J. Chen, B. Illarionov, A. Bacher, M. Fischer, I. Haase, G. Georg, Q. Ye, Z. Ma, and M.
Cushman, "A High-Throughput Screen Utilizing the Fluorescence of Riboflavin for
Identification of Lumazine Synthase Inhibitors," Anal. Biochem. 338, 124-130 (2005).
201. S. Antony, G. Kohlhagen, K. Agama, M. Jayaraman, S. Cao, F. Durrani, Y. M. Rustum,
M. Cushman, and Y, Pommier, "Cellular Topoisomerase I Inhibition and
Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline
Topoisomerase I Poison," Mol. Pharmacol. 67, 523-530 (2005).
202. B. L. Staker, M. D. Feese, M. Cushman, Y. Pommier, D. Zembower, L. Stewart, and A.
B. Burgin, "Structures of Three Classes of Anticancer Agents Bound to the Human
Topoisomerase I-DNA Covalent Complex, " J. Med. Chem. 48, 2336-2345 (2005).
203. E. Morgunova, W. Meining, B. Illarionov, I. Haase, G. Jin, A. Bacher, M. Cushman, M.
Fischer, and R. Ladenstein, "Crystal Structure of Lumazine Synthase from
Mycobacterium tuberculosis as a Target for Rational Drug Design: Binding Mode of a
New Class of Purinetrione Inhibitor," Biochemistry 44, 2746-2758 (2005).
204. X. Xiao, Z.-H Miao, S. Antony, Y. Pommier, and M. Cushman,
"Dihydroindenoisoquinolines Function as Prodrugs of Indenoisoquinolines," Bioorg.
Med. Chem. Lett 15, 2795-2798 (2005).
205. X. Xiao, S. Antony, Y. Pommier, and M. Cushman, "On the Binding of Indeno[1,2-
c]isoquinolines in the DNA-Topoisomerase I Cleavage Complex," J. Med. Chem. 48,
3231-3238 (2005).
206. A. Ioanoviciu, S. Antony, Y. Pommier, B. L. Staker, L. Stewart, and M. Cushman,
"Synthesis and Mechanism of Action Studies of a Series of Norindenoisoquinoline
Topoisomerase I Poisons Reveal an Inhibitor with a Flipped Orientation in the Ternary
DNA-Enzyme-Inhibitor Complex As Determined by X-Ray Crystallographic Analysis,"
J. Med. Chem. 48, 4803-4814 (2005).
207. H. Y. Kim, C. Patkar, R. Warrier, R. Kuhn, and M. Cushman, "Design, Synthesis, and
Evaluation of Dioxane-Based Antiviral Agents Targeted Against the Sindbis Virus
Capsid Protein," Bioorg. Med. Chem. Lett. 15, 3207-3211 (2005).
208. X. Xiao and M. Cushman, "An Ab Initio Quantum Mechanics Calculation that Correlates
with Ligand Orientation and DNA Cleavage Site Selectivity in Camptothecin-DNA-
Topoisomerase I Ternary Cleavage Complexes," J. Amer. Chem. Soc. 127, 9960-9961
(2005).
209. X. Xiao and M. Cushman, "A Facile Method to Transform trans-4-Carboxy-3,4-dihydro-
3-phenyl-1(2H)-isoquinolines to Indeno[1,2-c]isoquinolines," J. Org. Chem. 70, 6496-
6498 (2005).
210. X. Xiao and M. Cushman, "The Effect of E-ring Modifications in Camptothecin on
Topoisomerase I Inhibition: A Quantum Mechanics Treatment," J. Org. Chem. 70, 9584-
9587 (2005).
211. B.-L. Deng, T. L. Hartman, R. W. Buckheit, Jr., C. Pannecouque, E. De Clercq, P. E.
Fanwick, and M. Cushman, "Synthesis, Anti-HIV Activity, and Metabolic Stability of
New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors," J.
Med. Chem. 48, 6140-6155 (2005).